Table 3. Multivariable Associations Between eGFR Values and Lipid Parameters.

Lipid Parameter	Model 1		Model 2		Model 3		Model 4
	Beta Coefficient	P Value	Beta Coefficient	P Value	Beta Coefficient	P Value	Beta Coefficient	P Value
TC	0.029	0.28	0.010	0.70	−0.024	0.34	−0.020	0.42
HDL-C	0.012	0.64	−0.004	0.869	0.012	0.61	0.016	0.52
LDL-C	0.065	0.016	0.044	0.083	0.015	0.556	0.015	0.56
VLDL-C	−0.037	0.16	−0.034	0.206	−0.062	0.02	−0.061	0.02
TG	−0.036	0.17	−0.024	0.342	−0.068	0.009	−0.066	0.01
ApoA-I	0.026	0.36	0.016	0.569	0.039	0.18	0.047	0.11
ApoA-II	0.012	0.70	0.028	0.359	0.035	0.27	0.040	0.21
ApoB	0.053	0.09	0.039	0.182	−0.007	0.81	−0.006	0.85
ApoC-III	−0.075	0.02	−0.070	0.02	−0.111	0.001	−0.109	0.001
ApoE	−0.001	0.97	−0.008	0.801	−0.023	0.48	−0.014	0.67
Lp(a)	−0.085	<0.001	−0.089	<0.001	−0.089	<0.001	−0.087	0.001
FFA	0.031	0.30	0.027	0.361	0.024	0.44	0.022	0.47

Data represent standardized coefficients of change in log-transformed values of listed lipid fractions for every 10 ml/min/1.73 m² higher eGFR. Linear regression was performed in incremental models with the following co-variates.

Model 1: Age, gender, race.

Model 2: Age, gender, race, BMI, hypertension, lipid-lowering medications (statin, fibrate, niacin).

Model 3: Age, gender, race, BMI, hypertension, lipid-lowering medications, hemoglobin A1c, HOMA-IR, duration on insulin.

Model 4: Age, gender, race, BMI, hypertension, lipid-lowering medications, hemoglobin A1c, HOMA-IR, duration on insulin, urinary ACR.

*Definition of hypertension includes the use of anti-hypertensive medications.

**Statistically significant results are presented in bold.